Sugi Predict

Sugi Predict / Targets / ACVR1

ACVR1

Activin receptor type-1 · Q04771 · ACVR1 on Sugi Atlas →

90,606 patent compounds predicted against ACVR1, 51,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL232428 SCHEMBL232428 0.50 11/20
SCHEMBL188755 SCHEMBL188755 0.76 8/20
SCHEMBL182838 SCHEMBL182838 0.61 8/20
SCHEMBL335755 SCHEMBL335755 0.59 8/20
SCHEMBL266542 SCHEMBL266542 0.56 8/20
Pd-0166285 Pd-0166285 (SCHEMBL133914) 1.00 7/20
SCHEMBL35327 SCHEMBL35327 0.52 5/20
SCHEMBL20198 SCHEMBL20198 0.45 5/20
SCHEMBL20504 SCHEMBL20504 0.55 4/20
SCHEMBL188862 SCHEMBL188862 0.53 4/20
SCHEMBL334691 SCHEMBL334691 0.49 4/20
SCHEMBL325052 SCHEMBL325052 0.48 4/20
SCHEMBL175698 SCHEMBL175698 0.42 4/20
Allopurinol Allopurinol (SCHEMBL137085) 0.41 4/20
Quinazolinone Quinazolinone (SCHEMBL88525) 0.59 3/20
SCHEMBL189162 SCHEMBL189162 0.55 3/20
SCHEMBL198641 SCHEMBL198641 0.50 3/20
SCHEMBL255446 SCHEMBL255446 0.50 3/20
SCHEMBL349009 SCHEMBL349009 0.48 3/20
SCHEMBL340759 SCHEMBL340759 0.46 3/20

Clinical trials — most relevant to ACVR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies PHASE2/PHASE3NOT_YET_RECRUITING
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) PHASE2COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer PHASE2COMPLETED
A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults PHASE1NOT_YET_RECRUITING
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy PHASE1COMPLETED
Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases EARLY_PHASE1UNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension nanCOMPLETED
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia nanRECRUITING
Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia nanNOT_YET_RECRUITING
Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension. nanRECRUITING
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers nanCOMPLETED
Luspatercept in Metastatic AGCT of the Ovary nanCOMPLETED
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
StratosPHere (Non-interventional Study) nanCOMPLETED
Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital nanNOT_YET_RECRUITING
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia nanCOMPLETED
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension nanCOMPLETED
Influence of Sarcopenia on the Course of the Diseases nanRECRUITING
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals nanRECRUITING
European Registry of Acutely Decompensated Pulmonary Arterial Hypertension nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ACVR1 binder may also engage these)

ProteinNameSimilarity
BMPR1B Bone morphogenetic protein receptor type-1B 1.000 landscape →
Q28041 — 1.000 Q28041 →
Q05438 — 1.000 Q05438 →
Q61271 — 1.000 Q61271 →
P80202 — 1.000 P80202 →
Q90ZK6 — 1.000 Q90ZK6 →
Q78EA7 — 1.000 Q78EA7 →
P37172 — 1.000 P37172 →
P80201 — 1.000 P80201 →
P80204 — 0.999 P80204 →
Q64729 — 0.999 Q64729 →
P70539 — 0.997 P70539 →
O46680 — 0.996 O46680 →
P36895 — 0.996 P36895 →
Q5CD18 — 0.996 Q5CD18 →
P80203 — 0.995 P80203 →
Q8NER5 — 0.993 Q8NER5 →
Q61288 — 0.992 Q61288 →
P36898 — 0.992 P36898 →
Q8K348 — 0.992 Q8K348 →
Q24468 — 0.991 Q24468 →
ACVR1B Activin receptor type-1B 0.990 landscape →
TGFBR1 TGF-beta receptor type-1 0.990 landscape →
BMPR1A Bone morphogenetic protein receptor type-1A 0.987 landscape →
Q09488 — 0.987 Q09488 →
Q5RAN0 — 0.986 Q5RAN0 →
EPHA6 Ephrin type-A receptor 6 0.985 landscape →
P54757 — 0.985 P54757 →
P54755 — 0.985 P54755 →
Q07498 — 0.983 Q07498 →